Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Rapid7, Raises Price Target to $97

Morgan Stanley maintains Rapid7 (NASDAQ:RPD) with a Equal-Weight and raises the price target from $94 to $97.

byBenzinga Newsdesk

August 5, 2021

1 minute read

Morgan Stanley maintains Rapid7 (NASDAQ:RPD) with a Equal-Weight and raises the price target from $94 to $97.

Cantor Fitzgerald Initiates Coverage On Ascend Wellness Holdings with Neutral Rating, Announces Price Target of $1.75

By Benzinga Newsdesk

Today, 2:48 AM

Cantor Fitzgerald analyst Pablo Zuanic initiates coverage on Ascend Wellness Holdings (OTC:AAWH) with a Neutral rating and announces Price Target of $1.75.

AAWH

Stephens & Co. Reiterates Equal-Weight on Restaurant Brands Intl, Maintains $63 Price Target

By Benzinga Newsdesk

Today, 2:48 AM

Stephens & Co. analyst Joshua Long reiterates Restaurant Brands Intl (NYSE:QSR) with a Equal-Weight and maintains $63 price target.

QSR

Keybanc Upgrades AppFolio to Overweight, Announces $143 Price Target

By Benzinga Newsdesk

Today, 2:48 AM

Keybanc analyst Jason Celino upgrades AppFolio (NASDAQ:APPF) from Sector Weight to Overweight and announces $143 price target.

APPF

Clene Nanomedicine Presents Updated Data From Mid-Stage Amyotrophic Lateral Sclerosis Trials

By Vandana Singh

Today, 2:48 AM

Clene Inc (NASDAQ: CLNN) has announced multiple presentations of

CLNN

Morgan Stanley Maintains Equal-Weight on Rapid7, Raises Price Target to $97

Related Posts

Cantor Fitzgerald Initiates Coverage On Ascend Wellness Holdings with Neutral Rating, Announces Price Target of $1.75

Stephens & Co. Reiterates Equal-Weight on Restaurant Brands Intl, Maintains $63 Price Target

Keybanc Upgrades AppFolio to Overweight, Announces $143 Price Target

Clene Nanomedicine Presents Updated Data From Mid-Stage Amyotrophic Lateral Sclerosis Trials